Gastro Center of Maryland (GCM), one of the state’s largest GI practices, announces expansion to serve more patients across the DMV. With locations in Annapolis, Bethesda, Columbia, Gaithersburg, Olney, Riverdale, Silver Spring, Timonium, and White Marsh, GCM offers comprehensive digestive care including colonoscopies, endoscopies, and advanced treatments. State-of-the-art facilities feature onsite pathology and an IBD Infusion Center. Same-week and NextDay appointments available. Now welcoming new patients.

Silver Spring, Maryland, United States, 1st Dec 2025 – Gastro Center of Maryland (GCM), one of the largest and most respected gastroenterology practices in the state, recently announced its continued expansion with the addition of Silver Spring and Bethesda Location. This strategic growth reinforces the organization’s commitment to delivering expert, compassionate digestive care closer to home for patients throughout Maryland and the greater DMV region.

With this expansion, Gastro Center of Maryland now operates 9 locations across the state, including Annapolis, Bethesda, Columbia, Gaithersburg, Olney, Riverdale, Silver Spring, Timonium/Lutherville, and White Marsh. The practice’s growth comes in direct response to increasing demand for specialized gastroenterological services as digestive health conditions continue to rise nationwide.

“Our mission has always been to provide exceptional, patient-centered digestive care to every community we serve,” said Sarah, an employee. “This expansion allows us to bring our expertise, advanced technology, and compassionate approach to even more patients who deserve convenient access to world-class gastroenterology services.”

Gastro Center of Maryland specializes in diagnosing and treating a comprehensive range of digestive and liver conditions, including acid reflux, irritable bowel syndrome (IBS), Crohn’s disease, ulcerative colitis, hepatitis, fatty liver disease, and colon cancer. The practice operates state-of-the-art Ambulatory Surgery Centers equipped with the latest medical technology, offering advanced procedures such as Bravo pH testing, PillCam capsule endoscopy, STRETTA for reflux treatment, and the Orbera gastric balloon system for weight loss.

Patients benefit from GCM’s integrated care model, which includes onsite pathology services and an IBD Infusion Center for faster, more accurate diagnoses and treatments. The practice also offers same-week and NextDay GI appointments, ensuring patients receive timely care when they need it most.

Gastro Center of Maryland accepts most major insurance plans, including private insurance, federally sponsored plans, and covered Maryland plans. New patients are welcome and can schedule appointments by calling (410) 290-6677 or visiting www.gastromaryland.com.

Media Contact

Organization: Gastro Center of Maryland

Contact Person: Daniel Dent

Website: https://www.gastromaryland.com/

Email:
christiang@gastrocenter.com

Contact Number: +14102906677

Address:10301 Georgia Ave #208

City: Silver Spring

State: Maryland

Country:United States

Release id:38186

The post Gastro Center of Maryland Expands Footprint, Bringing Expert Digestive Care to More Communities Across the DMV appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

In a significant move to harness technology for social good, the ECI@Charity Digital Philanthropy Innovation Committee was officially launched today at the Asia Philanthropy Forum in Boao. The establishment of this global platform marks a strategic evolution for ECI, positioning it from an innovation observer to a proactive builder in the philanthropic sector, leveraging the unique opportunities presented by the Hainan Free Trade Port.

Under the theme “Open Collaboration, Innovative Development,” the Forum gathered over 600 delegates from 16 countries and regions, including government officials, heads of international organizations, philanthropists, and leading entrepreneurs. The event was organized by the Hainan Asia Philanthropy Research Institute under the guidance of the China NGO Network for International Exchanges.

A First-of-its-Kind Global Platform

The ECI@Charity Committee stands as the world’s first cross-border platform dedicated to channeling digital innovation toward improving the lives and well-being of persons with disabilities. Its mission is to foster a more inclusive and caring digital society, enabling individuals with disabilities to achieve greater health, happiness, and dignity through technological empowerment.

Dr. Owen Jia, Global Initiator of ECI, addressed the Asian Philanthropy Forum on “ Powering Good with Digital, Reshaping Giving with Innovation “.

“We are bringing technological innovation back to its humanistic roots,” said Dr. Owen Jia, Global Initiator of the ECI Awards. “By focusing on fundamental human needs, we embark on a new journey of ‘Innovation for Good.’ This committee represents a concrete step toward our vision of serving as a ‘Nobel Prize for the innovation field.’”

Dr. Owen Jia (left), Global Initiator of ECI Awards, and Mr. Shouzhen Xu (right), Co-Chairman of Asian Philanthropy Forum and Executive Chairman of ECI@Charity.

To lead this initiative, Dr. Jia has appointed Mr. Xu Shouzhen as the Executive Chairman of ECI@Charity. Mr. Xu, who also serves as Co-Chairman of the Boao Forum for Asian Philanthropy, will spearhead efforts to consolidate top-tier global innovation resources. “Our goal is to build a transformative collaboration platform that delivers practical, tech-driven solutions in areas like digital healthcare and accessible entertainment,” stated Mr. Xu.

Four-Pillar Action Framework

The Committee will drive impact through four core initiatives:

1. Research & Insights: Publishing an annual “White Paper on Digital Life Needs and Technological Innovation for Persons with Disabilities.”

2. Connection & Co-creation: Hosting the “ECI@Charity Tech for Good Innovation Summit” and “Tech for Disability Innovation Marathon.”

3. Catalyzation & Implementation: Establishing an “ECI@Charity Seed Fund” and a curated “Solutions Resource Library.”

4. Recognition & Promotion: Integrating the specialized “ECI@Charity Awards” into the esteemed ECI Awards framework to benchmark excellence.

First Wave of Initiative Projects Launched

Concurrently, the Committee launched three initiative projects: the “Digital Healing” Partnership Program, connecting digital health enterprises with rehabilitation institutions; the “Accessible Gaming” Developers Alliance, formulating and promoting accessible game design standards; and the “Heartvoice Connect” Public Welfare Communication project, utilizing digital technologies to showcase the talents of artists with disabilities.

Launch Projects and Strategic Support

The Committee announced three flagship partnership programs at launch:

· The “Digital Healing” Partnership Program, linking digital health enterprises with rehabilitation institutions.

· The “Accessible Gaming” Developers Alliance, to formulate and promote inclusive game design standards.

· The “Heartvoice Connect” Public Welfare Communication project, using digital tools to amplify the talents of artists with disabilities.

Mr. James George, Deputy Resident Representative of the United Nations Development Programme (UNDP) in China, delivered a speech at the opening ceremony of the Asian Philanthropy Forum.

The initiative received notable support from the international community. Mr. James George, Deputy Resident Representative of the United Nations Development Programme (UNDP) in China, addressed the Forum, underscoring the importance of multi-stakeholder partnerships in achieving sustainable development goals.

2025 Asian Philanthropy Forum

Looking Ahead

Positioned at the new frontier of digital civilization, ECI@Charity will utilize the open policy framework of the Hainan Free Trade Port to aggregate global innovators. It aims to contribute substantively to a more equitable, inclusive, and compassionate digital future, solidifying its transition from an innovation observer to a definitive leader in shaping that future.

About ECI Awards

The ECI Awards (International Awards for Innovation in Business and Marketing), organized by the International Entrepreneurs, Creatives & Innovators Association (IECIA), is a globally recognized accolade celebrating innovation that creates new market value. It honors achievements across business models, products, services, technology, marketing, and social innovation.

Media Contact

Organization: Secretary General of EClAwards Committee

Contact Person: Faye Feng

Website: https://www.eciawards.org.cn

Email: Send Email

City: BOAO

Country:China

Release id:38261

The post New Digital Philanthropy Initiative Launched at Asia Philanthropy Forum in Boao appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Santersus AG Announces Advancement of NucleoCapture into Pivotal Clinical Development strengthened by Strategic Collaboration with Terumo

Zurich, Switzerland, 1st Dec 2025 – Santersus AG today announced the successful completion of its Series A financing, led by Norcliffe, a UK life sciences fund with participation from Terumo Ventures. The financing will support the advancement of Santersus’ NucleoCapture into pivotal clinical development while accelerating progress across Santersus’ broader pipeline.

Santersus has entered a strategic collaboration with Terumo Blood and Cell Technologies to advance NucleoCapture(TM) for the treatment of sepsis, a disease that kills 11M people worldwide each year. The collaboration integrates Santersus’ first-in-class NucleoCapture blood purification device with Terumo BCT’s industry-leading Spectra Optia Apheresis System, creating a novel therapeutic apheresis approach designed to selectively remove neutrophil extracellular traps (NETs)— a major contributor to systemic inflammation and sepsis-related organ dysfunction. NucleoCapture has previously been granted two U.S. FDA Breakthrough Device Designations, including one for the treatment of sepsis.

Under this collaboration, Santersus will lead the pivotal NUC-CAP clinical trial across the United States, United Kingdom, Switzerland and Europe. Terumo BCT will support the clinical development of the program, and Terumo Ventures – the corporate VC arm of Terumo – has invested in Santersus’ Series A financing round to accelerate the development of this technology for a critical unmet need with high mortality.

“Therapeutic apheresis has untapped potential to address serious unmet medical needs,” said Veerle d’Haenens, General Manager of Global Therapy Innovations at Terumo Blood and Cell Technologies. “Our partnership with Santersus reflects our commitment to advancing innovative treatment options for critically ill patients.”

The Series A financing will also support Santersus’ preparation for pivotal clinical trials in systemic lupus erythematosus (SLE), where NucleoCapture has received its second U.S. FDA Breakthrough Device Designation for treatment-refractory disease. The pivotal SLE program addressing an estimated $4bn global treatment market – will expand Santersus’ late-stage clinical portfolio beyond critical care and is expected to begin following the sepsis study launch.

Santersus is also advancing NucleoCapture technology into solid-organ transplantation, including a program designed to perfuse and recondition heavily damaged donor livers prior to transplantation. The global organ transplantation market is projected to reach $61.5bn by 2027. In parallel, Santersus is expanding a NucleoCapture program in lung transplantation focused on the prevention of primary graft dysfunction (PGD). Together, these initiatives support the application of NucleoCapture across solid-organ transplantation.

Santersus is also advancing early-stage development of NucleoCapture for Alzheimer’s disease, with an exploratory clinical study under way to assess its effects on amyloid removal. The global Alzheimer’s therapeutics market is valued at approximately $5bn in 2025 and is projected to double over the next decade.

These integrated programs reflect Santersus’ transition towards a multi-indication, late-stage clinical development company and position Santersus as a leading developer of NETs-targeted therapeutic apheresis technologies across critical care, autoimmunity, solid-organ transplantation, and neurodegeneration.

About Santersus AG

Zurich-based Santersus AG is a biotechnology company developing NucleoCapture, a novel, patent-protected extracorporeal blood purification technology designed to selectively remove cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs). NucleoCapture has received two U.S. FDA Breakthrough Device Designations: one for the treatment of sepsis and one for systemic lupus erythematosus. Santersus is advancing a diversified clinical pipeline across sepsis, systemic lupus erythematosus, solid-organ transplantation (liver and lung), and Alzheimer’s disease.

For more information, please visit www.santersus.com

Media Contact

Organization: Santersus AG

Contact Person: Aleksander Zaporoztsev

Website: https://www.santersus.com

Email:
info@santersus.com

Country:Switzerland

Release id:38172

The post Santersus AG Completes Series A Financing and Announces Strategic Collaboration with Terumo Corporation appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section